Drugs / GSK3536820A
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03652610 | Sep 2018 → Jan 2019 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03433482 | Aug 2018 → Jul 2019 | meningococcal meningitis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3536820A | “investigational MenACWY liquid vaccine (GSK3536820A)” NCT03433482 ↗ |
| Known as | MenACWY liquid | “investigational MenACWY liquid vaccine (GSK3536820A)” NCT03433482 ↗ |
| Modality | Vaccine | “Meningococcal ACWY Conjugate Vaccine” NCT03652610 ↗ |
| Route | Intramuscular | “Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm” NCT03652610 ↗ |